カワチ薬品 released its interim results for the fiscal year ending March 2027, reporting ordinary profit of ¥3,468 million. Its full-year ordinary profit forecast is ¥6,000 million, unchanged from the previous forecast, implying a 24% decline in profit.
カワチ薬品 announced its interim results for the fiscal year ending March 2027, reporting ordinary profit of ¥3,468 million. This was broadly in line with the market's prior expectations, and the earnings forecast released the same day maintained the full-year ordinary profit forecast at ¥6,000 million. The earnings summary indicates that interim results were broadly in line with the company's expectations.
The full-year outlook announced the same day is expected to be lower than the previous year, with profit forecast to decline by approximately 24%. As a result, full-year ordinary profit remains forecast at ¥6,000 million, maintaining the current forecast level.
Related stocks cited on the same day included Joshi n, イオン九州, オイシックス and コジマ, and attention is also focused on the performance of these stocks, which have attracted market interest.